First healthy volunteer dosed in study of HER-096 for Parkinson’s
The first healthy volunteer has been dosed in a clinical study that will test the safety and efficacy of Herantis Pharma’s HER-096 treatment candidate for Parkinson’s disease, the company announced in a press release. The Phase 1a clinical trial also is evaluating the ability of HER-096 to penetrate…